How much cash does PTC Therapeutics generate?

PTC Therapeutics (PTCT) generated $704.1M in operating cash flow over the trailing twelve months.

What is PTC Therapeutics's free cash flow?

After $8.3M of capital expenditures, PTC Therapeutics's free cash flow was $696.9M over the trailing twelve months, up 637.5% year over year.

Where does PTC Therapeutics's cash flow data come from?

Every line is extracted from PTC Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

PTC Therapeutics PTCT Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	——	——	$751.72M+266%	$629.17M+231%	$594.84M+203%
Depreciation and amortization	$47.01M+71.0%	$38.82M-48.7%	$32.68M-78.2%	$28.05M-86.3%	$27.49M-89.0%
Stock-based compensation	$79.91M+7.6%	$74.55M-0.1%	$73.27M-0.8%	$73.6M-9.2%	$74.3M-18.5%
Deferred income taxes	——	——	——	——	-$55.91M-9.8%
Amortization of debt issuance costs	$1.23M+2.0%	$1.22M+1.8%	$1.21M+1.9%	$1.21M-17.4%	$1.2M-30.6%
Change in inventories	$53.44M+749%	$53.9M+974%	$16.03M—	$611K—	-$8.24M—
Change in accounts payable	——	——	——	——	——
Change in other assets	——	——	——	——	$2.38M-72.7%
Change in other liabilities	——	——	-$9.93M-88.0%	-$2.6M—	$5.39M—
Change in deferred revenue	——	——	——	——	——
Net gains (losses) on investments	——	——	——	——	——
Non-cash operating lease expense	$7.44M-4.0%	$7.47M-3.7%	$7.12M-10.4%	$6.91M-19.8%	$7.75M-10.7%
Change in fair value of contingent consideration	——	——	——	——	-$5.18M+96.1%
Change in receivables	——	——	——	——	$6.56M—
Net cash from operating activities	——	——	——	——	$691.65M+1,289%
Capital expenditures	$8.33M—	$8.86M—	$10.25M—	$7.33M—	——
Purchases of investments	$1.5B+81.1%	$1.36B+124%	$1.18B+127%	$1.16B+207%	$825.95M+252%
Proceeds from maturities/sales of investments	$1.02B+63.8%	$783.9M+42.6%	$683.12M—	$660.11M—	$624.71M—
Purchases of intangible assets	$290.5M+2,006%	$291.15M+330%	$258.97M+195%	$16.47M-83.6%	$13.79M-87.9%
Proceeds from sale of property, plant and equipment	——	——	——	——	——
Net cash from investing activities	-$805.37M-3,090%	-$895.99M-2,128%	-$628.28M-97.6%	-$381.33M-25.1%	-$25.25M+90.4%
Proceeds from issuance of common stock	$83.75M+98.1%	$93.1M+226%	$56.96M+919%	$40.7M+381%	$42.29M+107%
Other financing activities	——	——	——	——	$19.99M—
Net cash from financing activities	$328.09M+16.2%	$331.09M+21.1%	$55.06M-93.7%	$39.84M-95.4%	$282.36M-56.1%
Effect of exchange rate changes on cash	——	——	——	$18.87M—	$95K—
Net increase (decrease) in cash	——	——	——	——	$931.24M+181%
Interest paid	——	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$19.82M+77.9%	$18.02M+43.8%	$15.55M+29.0%	$12.41M+36.2%	$11.15M+91.8%
Amortization expense related to capitalized debt issuance costs	$1.23M+2.0%	$1.22M+1.8%	$1.21M+1.9%	$1.21M-17.4%	$1.2M-30.6%
Contingent consideration fair value adjustments	——	——	——	——	-$5.18M+96.1%
Clearpoint Equity Investment Fvni Unrealized Gain Loss	——	——	——	——	$4.55M—
Equity Securities, FV-NI, Realized Gain (Loss)	——	——	——	——	——
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	——	——	——	$5.29M+440%	$8.44M+123%
Gain Loss On Disposition And Impairment Of Tangible Assets	——	——	——	——	——
Gain Loss On Extinguishment Of Debt Sale Of Future Royalties And Debt Issuance Costs	——	——	——	——	——
Gain Loss On Modification Of Lease	——	$10.78M+97.2%	$9.45M—	$8.12M—	$6.79M—
Gain Loss On Priority Review Voucher	——	——	——	——	——
Increase Decrease In Contingent Consideration	——	——	——	——	-$6.03M—
Increase (Decrease) in Deposit Assets	-$1.66M—	-$2.64M—	-$6.05M—	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	$2.38M-72.7%
Noncash Interest Expense Liability Related To Sale Of Future Royalties	$231.2M+11.7%	$215.16M+3.7%	$201.66M-1.0%	$204.38M+20.7%	$206.99M+52.3%
Noncash Royalty Revenue Sale Of Future Royalties	$242.43M+28.1%	$228.57M+25.9%	$201.79M+17.5%	$193.26M+40.3%	$189.25M+79.5%
Operating lease right-of-use asset amortization	$7.44M-4.0%	$7.47M-3.7%	$7.12M-10.4%	$6.91M-19.8%	$7.75M-10.7%
Payments to Acquire Intangible Assets	$290.5M+2,006%	$291.15M+330%	$258.97M+195%	$16.47M-83.6%	$13.79M-87.9%
Sale of investments	$1.02B+63.8%	$783.9M+42.6%	$683.12M—	$660.11M—	$624.71M—
Proceeds from disposals of property, plant and equipment	——	——	——	——	——
Decrease In Operating Lease Liability Related To Lease Modifications And Terminations	——	——	——	——	——
Decrease In Operating Lease Right Of Use Assets Related To Lease Modifications And Terminations	——	——	——	——	——
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	——	——	——	$18.87M—	$95K—
U.S. federal	——	$26.64M—	——	——	——
Purchases of intangible assets included in accrued expenses and other liabilities	——	——	——	——	——
Noncash Or Part Noncash Fixed Assets Tenant Improvement Allowance	——	$766K—	$939K—	$2.49M—	——
Proceeds From Sale Of Priority Review Voucher	——	——	——	——	——
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	$5.59M—
Free cash flow	——	——	——	——	$693.02M+907%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about PTC Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does PTC Therapeutics generate?: PTC Therapeutics (PTCT) generated $704.1M in operating cash flow over the trailing twelve months.
What is PTC Therapeutics's free cash flow?: After $8.3M of capital expenditures, PTC Therapeutics's free cash flow was $696.9M over the trailing twelve months, up 637.5% year over year.
Where does PTC Therapeutics's cash flow data come from?: Every line is extracted from PTC Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.